Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001506251 XXXXXXXX LIVE 1 Common Shares, $0.0001 par value per share 07/17/2025 false 0001851484 17331Y109 Citius Oncology, Inc. 11 Commerce Drive 1st Floor Cranford NJ 07016 Alexander M. Donaldson, Esq. (919) 781-4000 Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh NC 27607 0001506251 N Citius Pharmaceuticals, Inc. OO N X1 66049615.00 0.00 66049615.00 0.00 66049615.00 N 84.3 CO CO Common Shares, $0.0001 par value per share Citius Oncology, Inc. 11 Commerce Drive 1st Floor Cranford NJ 07016 EXPLANATORY NOTE On July 17, 2025, the Issuer sold and issued 6,818,182 shares of its common stock, $0.0001 par value per share, in a public offering. This Amendment No. 1 to the Schedule 13D of the Reporting Person filed on August 16, 2024, amends and supplements the Schedule 13D as specifically set forth herein, to give effect to the issuance of the shares on July 17, 2025. The Reporting Person is the beneficial owner of 66,049,615 shares of the Issuer's common stock, which represents approximately 84.3% of the Issuer's outstanding common stock, based upon 78,370,402 shares of common stock outstanding as of July 17, 2025. The Reporting Person has sole voting and dispositive power of 66,049,615 shares of the Issuer's common stock beneficially owned. Citius Pharmaceuticals, Inc. /s/ Leonard Mazur Leonard Mazur / Chief Executive Officer 07/25/2025